GLP-1 receptor agonists like semaglutide may offer anti-inflammatory benefits that could improve treatment of type 2 diabetes and related conditions. "I'm quite convinced ... that treatment of inflammation is going to become part of our treatment [of T2D]," said Dr. Marc Donath said at a meeting of Diabetes Canada and the Canadian Society of Endocrinology and Metabolism.

A study in the journal Nutrients found that alternate-day fasting over four weeks led to significant reductions in body and fat mass but also reduced muscle mass. The study involved 37 men with an average BMI of 26. Researchers found that whey protein supplements did not prevent muscle loss.

Glucagon-like peptide-1 receptor agonists may help more patients with higher BMIs become eligible for joint replacement by aiding weight loss, which may also alleviate arthritis and joint pain. "Significant weight loss can delay the need for total joint replacement by reducing stress and inflammation, thereby improving pain and function," said Dr. Cameron Ledford. However, a study presented at a meeting of the American College of Lifestyle Medicine found people taking GLP-1 drugs were more likely to fill opioid prescriptions.

A Concise Clinical Guidance report from the American College of Cardiology supports the FDA's proposal to require front-of-package nutrition labeling on food products, citing the potential to improve diet quality, reduce cardiovascular disease risk and advance equity in public health. The FDA proposal would require manufacturers to add boxes to the front of packages showing levels of sodium, added sugar and saturated fat, according to the clinical guidance in the Journal of the American College of Cardiology.

American College of Physicians President Dr. Jason Goldman discusses challenges faced by private practice physicians, including stagnant reimbursement rates, government regulations and administrative tasks. Goldman says advocacy is needed to address these issues and improve the health care system. "[A]s an internal medicine specialist, we are actually making a healthier population, but all of these regulations and payment issues are preventing us from doing what we're meant to do, which is simply take care of the patients and make them healthier," Goldman said.

The FDA has cleared an updated algorithm for the Omnipod 5 automated insulin delivery system, allowing users to set glucose targets as low as 100 mg/dL. The new algorithm, set to launch in the US in the first half of 2026, introduces six new glucose targets ranging from 100 mg/dL to 150 mg/dL in 10 mg/dL increments.

Abbott has expanded access to its Lingo over-the-counter continuous glucose monitor by making it available for Android users in the Google Play Store, in addition to iOS devices. The biowearable, built on Abbott's FreeStyle Libre technology, is designed for consumers 18 and older who are not on insulin. The device provides real-time glucose tracking, personalized insights and coaching to help users improve their health and wellness.

The Trump administration is pushing airports to offer healthier food options, family-friendly features and exercise equipment with a new $1 billion initiative. Transportation Secretary Sean Duffy has emphasized that these are not regulatory mandates but suggestions to enhance passenger comfort. Critics say the program sides